Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)
CAPS Rating:
A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.
Got Stock?
A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I am convienced AEZS is on the right track but only time will tell. I am betting on AEZS to succeed. After all the shares are cheap and owning some shares may be a good thing in the long run.